A Phase II, Randomized, Cross-Over, Vehicle-Controlled, Double-Blind, Multicenter Study of the Safety, Pharmacodynamics, and Preliminary Efficacy of GHRP-1/AG in Subjects With ESRD on Hemodialysis

NCT00381602 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of enrolment

Conditions

End Stage Renal Disease

Interventions

DRUG: GHRP-1/AG 70 mg depot in ESRD
OTHER: Placebo

Sponsor

QLT Inc.